Contrave's future in doubt as US FDA demands another cardiac study
This article was originally published in Scrip
The future of Orexigen Therapeutics/Takeda's obesity therapy Contrave (naltrexone HCl/bupropion HCl) looks highly uncertain after the US FDA said it wanted a further cardiovascular safety trial before it will approve the product. The request, outlined in a complete response letter, wiped more than 70% off of the US company's share price in early trading on 1 February.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.